In this Medtech Matters podcast episode of Mike on Medtech with Mike Drues, president of Vascular Sciences, we’re discussing what the process should be for a company once they receive a 483 or warning letter from the FDA. Best practices, first steps to take, who is responsible, and potential strategies for avoiding them are shared. Specifically, the following questions are addressed:
- Could you please explain what a 483 is and what a warning letter is? Are they the same thing?
- What are some common reasons or examples of why a company would get a 483 or warning letter?
- What are the first steps for a company that has just received a warning letter or 483?
- Who is responsible for the response to a 483 or warning letter? Does this fall to regulatory? Quality? Who really should be responsible for addressing it?
- Is it common for a company to get a warning letter or 483 for the same issue? If that happens, what then should the company do?
- What’s worse than a 483 or warning letter? Is there a higher level that really causes a concern for the company involved?
- What should be considered in terms of the PR hit as a result of a 483 or warning letter?
- Do you have suggestions with regard to preventing a 483 or warning letter?
- Anything more a company should consider and after that, please share what you consider to be the most important takeaways?
Listen to this discussion and see if you have a better handle on what to do if you get a 483 or warning letter. If you’d like to share thoughts, ask questions, or have a suggestion for a future topic for us to cover, please reach out to me at sfenske@rodmanmedia.com and we’ll see if we want to address your ideas/inquiries/suggestions in a future episode.
Send us a text
For more medtech news and information, visit https://www.mpomag.com.
